Skip to main content

Table 1 General characteristics and serum lipid levels between the controls and patients

From: Association of polymorphisms in the MAFB gene and the risk of coronary artery disease and ischemic stroke: a case–control study

Characteristic Controls (n = 539) Patients P
  CAD (n = 525) IS (n = 540) P 1 P 2 P 3
Male/female 374/165 383/142 390/150 0.223 0.316 0.837
Age, years 63.08 ± 10.76 62.27 ± 10.93 62.81 ± 12.36 0.222 0.702 0.448
Body mass index, kg/m2 22.84 ± 3.51 23.29 ± 3.33 24.75 ± 5.18 0.033 0.048 0.135
Systolic blood pressure, mmHg 133.18 ± 22.95 137.00 ± 23.28 147.54 ± 21.98 0.007 <0.001 <0.001
Diastolic blood pressure, mmHg 79.78 ± 13.03 81.82 ± 14.13 83.71 ± 12.92 0.014 <0.001 0.023
Pulse pressure, mmHg 54.38 ± 17.94 55.86 ± 18.19 63.80 ± 17.98 0.185 <0.001 <0.001
Cigarette smoking, n (%) 220(40.8) 233(44.4) 226(41.9) 0.264 0.757 0.421
Alcohol consumption, n (%) 232(43.0) 220(41.9) 198(36.7) 0.710 0.035 0.090
Total cholesterol, mmol/L 4.70 ± 1.18 4.61 ± 1.18 4.52 ± 1.15 0.217 0.014 0.232
Triglyceride, mmol/L 1.08(0.81) 1.21(0.80) 1.36(0.93) 0.026 <0.001 <0.001
HDL-C, mmol/L 1.48 ± 0.49 1.45 ± 0.51 1.23 ± 0.40 0.267 <0.001 <0.001
LDL-C, mmol/L 2.78 ± 0.93 2.71 ± 0.90 2.68 ± 0.90 0.255 0.083 0.555
Apolipoprotein (Apo) AI, g/L 1.17 ± 0.32 1.15 ± 0.29 1.02 ± 0.22 0.200 <0.001 0.288
ApoB, g/L 0.89 ± 0.23 0.90 ± 0.25 0.89 ± 0.25 0.574 0.882 0.692
ApoAI/ApoB 1.45 ± 1.76 1.37 ± 0.66 1.17 ± 0.61 0.366 0.001 <0.001
Type 2 diabetes mellitus, n (%) 75(13.9) 117(22.3) 116(21.5) <0.001 0.001 0.751
Hypertension, n (%) 174(32.3) 266(50.7) 289(53.5) <0.001 <0.001 0.107
Hyperlipidemia, n (%) 198(36.7) 210(40.0) 212(39.3) 0.284 0.415 0.851
Using lipid-lowing drugs, n (%) 0(0) 172(32.8) 150(27.8) <0.001 <0.001 0.077
  1. CAD coronary artery disease, IS ischemic stroke, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
  2. P 1: comparison of CAD and controls; P 2: comparison of IS and controls; P 3: comparison of CAD and IS